Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gain Therapeutics (GANX) Current Deferred Revenue (2020 - 2025)

Gain Therapeutics has reported Current Deferred Revenue over the past 6 years, most recently at $11293.0 for Q3 2025.

  • Quarterly results put Current Deferred Revenue at $11293.0 for Q3 2025, down 98.41% from a year ago — trailing twelve months through Sep 2025 was $11293.0 (down 98.41% YoY), and the annual figure for FY2024 was $252211.0, down 77.52%.
  • Current Deferred Revenue for Q3 2025 was $11293.0 at Gain Therapeutics, down from $22685.0 in the prior quarter.
  • Over the last five years, Current Deferred Revenue for GANX hit a ceiling of $1.4 million in Q3 2023 and a floor of $11293.0 in Q3 2025.
  • Median Current Deferred Revenue over the past 5 years was $259357.5 (2021), compared with a mean of $439851.4.
  • Biggest five-year swings in Current Deferred Revenue: skyrocketed 2352.96% in 2023 and later tumbled 98.41% in 2025.
  • Gain Therapeutics' Current Deferred Revenue stood at $266504.0 in 2021, then tumbled by 79.29% to $55180.0 in 2022, then soared by 1933.6% to $1.1 million in 2023, then plummeted by 77.52% to $252211.0 in 2024, then tumbled by 95.52% to $11293.0 in 2025.
  • The last three reported values for Current Deferred Revenue were $11293.0 (Q3 2025), $22685.0 (Q2 2025), and $217841.0 (Q1 2025) per Business Quant data.